{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:49:39Z","timestamp":1792097379592,"version":"4.4.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03397-1","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:19:18Z","timestamp":1789449558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the barrier: Engineering the tumor-immune-soil nexus\u2013a mechanistic blueprint for integrating Traditional Chinese Medicine with immunotherapy in metastatic colorectal cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Yu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"3","key":"3397_CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","volume":"36","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36(3):277\u201384.","journal-title":"Ann Oncol"},{"issue":"4","key":"3397_CR2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.5306\/wjco.v15.i4.540","volume":"15","author":"CG Niu","year":"2024","unstructured":"Niu CG, et al. Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status. World J Clin Oncol. 2024;15(4):540\u20137.","journal-title":"World J Clin Oncol"},{"key":"3397_CR3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101917","volume":"58","author":"M Fakih","year":"2023","unstructured":"Fakih M, et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine. 2023;58:101917.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"3397_CR4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","volume":"9","author":"M Fakih","year":"2023","unstructured":"Fakih M, et al. Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial. JAMA Oncol. 2023;9(5):627\u201334.","journal-title":"JAMA Oncol"},{"issue":"12","key":"3397_CR5","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1038\/s41588-025-02380-2","volume":"57","author":"A Henriques","year":"2025","unstructured":"Henriques A, et al. TGF-\u03b2 builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1(+) macrophages. Nat Genet. 2025;57(12):3050\u201365.","journal-title":"Nat Genet"},{"key":"3397_CR6","volume":"16","author":"P Wang","year":"2025","unstructured":"Wang P, et al. Disrupting \u03b2-catenin\/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer. Front Immunol. 2025;16:1662385.","journal-title":"Front Immunol"},{"issue":"1","key":"3397_CR7","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1186\/s12967-025-07097-8","volume":"23","author":"X Zhang","year":"2025","unstructured":"Zhang X, et al. MNDA promotes immunosuppression in microsatellite instability-high colorectal cancer by facilitating PMN-MDSC infiltration via H3K18 lactylation. J Transl Med. 2025;23(1):1049.","journal-title":"J Transl Med"},{"key":"3397_CR8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.117399","volume":"320","author":"X Kong","year":"2024","unstructured":"Kong X, et al. Mechanism of Qizhen decoction-mediated maturation of DC cells to activate the IL-12\/JAK2\/STAT4 pathway to sensitise PD-1 inhibitors in the treatment of colorectal cancer. J Ethnopharmacol. 2024;320:117399.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"3397_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12964-018-0218-1","volume":"16","author":"H Liu","year":"2018","unstructured":"Liu H, et al. Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1\/TS pathway. Cell Commun Signal. 2018;16(1):7.","journal-title":"Cell Commun Signal"},{"key":"3397_CR10","volume":"14","author":"S Lu","year":"2023","unstructured":"Lu S, et al. Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation. Front Immunol. 2023;14:1235575.","journal-title":"Front Immunol"},{"key":"3397_CR11","doi-asserted-by":"publisher","DOI":"10.2174\/0115672026420811260120042353","author":"Y Lin","year":"2026","unstructured":"Lin Y, et al. Research progress in immunotherapy and the impact of traditional Chinese medicine on glioblastoma. Current Neurovascular Research. 2026. https:\/\/doi.org\/10.2174\/0115672026420811260120042353.","journal-title":"Current Neurovascular Research"},{"issue":"1","key":"3397_CR12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7150\/jca.88854","volume":"15","author":"X Deng","year":"2024","unstructured":"Deng X, et al. Shenling Baizhu Decoction (SLBZD) may play a synergistic role of tirelizumab in the treatment of colorectal cancer by influencing the imbalance of colon flora and Tumor microenvironment. J Cancer. 2024;15(1):30\u201340.","journal-title":"J Cancer"},{"key":"3397_CR13","volume":"118","author":"X An","year":"2019","unstructured":"An X, et al. The interaction between the gut microbiota and herbal medicines. Biomed Pharmacother. 2019;118:109252.","journal-title":"Biomed Pharmacother"},{"key":"3397_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1389925","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, et al. Repairing gut barrier by traditional Chinese medicine: roles of gut microbiota. Frontiers in Cellular and Infection Microbiology. 2024. https:\/\/doi.org\/10.3389\/fcimb.2024.1389925.","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"key":"3397_CR15","volume":"128","author":"K Cai","year":"2024","unstructured":"Cai K, et al. Xianlian Jiedu decoction alleviates colorectal cancer by regulating metabolic profiles, intestinal microbiota and metabolites. Phytomedicine. 2024;128:155385.","journal-title":"Phytomedicine"},{"key":"3397_CR16","volume":"148","author":"Y Chen","year":"2025","unstructured":"Chen Y, et al. Huang-Lian-Jie-Du decoction enhances capecitabine-oxaliplatin efficacy via Akkermansia muciniphila and CD8+ T cells in colorectal cancer. Phytomedicine. 2025;148:157233.","journal-title":"Phytomedicine"},{"issue":"48","key":"3397_CR17","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.3748\/wjg.v26.i48.7633","volume":"26","author":"Y Li","year":"2020","unstructured":"Li Y, et al. Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patients via gut microbiota. World J Gastroenterol. 2020;26(48):7633\u201351.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"3397_CR18","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s11605-023-05654-4","volume":"27","author":"Q Li","year":"2023","unstructured":"Li Q, et al. Gut barrier dysfunction and bacterial lipopolysaccharides in colorectal cancer. J Gastrointest Surg. 2023;27(7):1466\u201372.","journal-title":"J Gastrointest Surg"},{"key":"3397_CR19","volume":"15","author":"CM Raynaud","year":"2024","unstructured":"Raynaud CM, et al. MUC2 expression modulates immune infiltration in colorectal cancer. Front Immunol. 2024;15:1500374.","journal-title":"Front Immunol"},{"issue":"7785","key":"3397_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","volume":"576","author":"S Hang","year":"2019","unstructured":"Hang S, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature. 2019;576(7785):143\u20138.","journal-title":"Nature"},{"key":"3397_CR21","doi-asserted-by":"crossref","unstructured":"Osswald A, et al. Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer. Gut, 2025.75(8), pp.1505-1519","DOI":"10.1136\/gutjnl-2024-332243"},{"key":"3397_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202514661","author":"Y Li","year":"2025","unstructured":"Li Y. Spatial transcriptomics and snRNA-seq expose CAF niches orchestrating dual stromal-immune barriers in hepatocellular carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2025. https:\/\/doi.org\/10.1002\/advs.202514661.","journal-title":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"12","key":"3397_CR23","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1007\/s00253-020-10527-w","volume":"104","author":"L Zhu","year":"2020","unstructured":"Zhu L, et al. Protective effect of baicalin on the regulation of Treg\/Th17 balance, gut microbiota and short-chain fatty acids in rats with ulcerative colitis. Appl Microbiol Biotechnol. 2020;104(12):5449\u201360.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"6","key":"3397_CR24","volume":"6","author":"T Hu","year":"2020","unstructured":"Hu T, et al. Myeloid-derived suppressor cells in cancer: mechanistic insights and targeted therapeutic innovations. MedComm (2020). 2020;6(6):e70231.","journal-title":"MedComm (2020)"},{"issue":"1","key":"3397_CR25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/2326-6066.CIR-20-0527","volume":"9","author":"JP V\u00e4yrynen","year":"2021","unstructured":"V\u00e4yrynen JP, et al. The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment. Cancer Immunol Res. 2021;9(1):8\u201319.","journal-title":"Cancer Immunol Res"},{"key":"3397_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16121562","author":"JLHLJ Li","year":"2024","unstructured":"Li JLHLJ, Wang Y. Engineered lubricative lecithin-based electrospun nanofibers for the prevention of postoperative abdominal adhesion. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16121562.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3397_CR27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000489982","volume":"47","author":"M Kuang","year":"2018","unstructured":"Kuang M, et al. Artesunate attenuates pro-inflammatory cytokine release from macrophages by inhibiting TLR4-mediated autophagic activation via the TRAF6-Beclin1-PI3KC3 pathway. Cell Physiol Biochem. 2018;47(2):475\u201388.","journal-title":"Cell Physiol Biochem"},{"key":"3397_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24102016","author":"W Wei","year":"2019","unstructured":"Wei W, et al. Astragalus polysaccharide RAP induces macrophage phenotype polarization to M1 via the Notch signaling pathway. Molecules. 2019. https:\/\/doi.org\/10.3390\/molecules24102016.","journal-title":"Molecules"},{"key":"3397_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13793","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wang J. Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy. Immunology. 2024. https:\/\/doi.org\/10.1111\/imm.13793.","journal-title":"Immunology"},{"issue":"1","key":"3397_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189061","volume":"1879","author":"BK Roberts","year":"2024","unstructured":"Roberts BK, Collado G, Barnes BJ. Role of interferon regulatory factor 5 (IRF5) in tumor progression: prognostic and therapeutic potential. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(1):189061.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"3397_CR31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01526","volume":"11","author":"I Sieminska","year":"2020","unstructured":"Sieminska I, Baran J. Myeloid-derived suppressor cells in colorectal cancer. Front Immunol. 2020;11:1526.","journal-title":"Front Immunol"},{"key":"3397_CR32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.intimp.2016.07.035","volume":"39","author":"D Liu","year":"2016","unstructured":"Liu D, et al. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer. Int Immunopharmacol. 2016;39:265\u201372.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"3397_CR33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/1940-6207.CAPR-11-0247","volume":"5","author":"SP Tu","year":"2012","unstructured":"Tu SP, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila). 2012;5(2):205\u201315.","journal-title":"Cancer Prev Res (Phila)"},{"key":"3397_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07636-3","author":"M Ge","year":"2026","unstructured":"Ge M, et al. Senescent fibroblasts drive CD8(+) T cell dysfunction in colorectal cancer via CD36-mediated lipid transfer and peroxidation. J Transl Med. 2026. https:\/\/doi.org\/10.1186\/s12967-025-07636-3.","journal-title":"J Transl Med"},{"issue":"6","key":"3397_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41419-019-1638-6","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv J, et al. Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment. Cell Death Dis. 2019;10(6):415.","journal-title":"Cell Death Dis"},{"key":"3397_CR36","volume":"128","author":"H Cui","year":"2024","unstructured":"Cui H, et al. Mechanic evaluation of Wu-Mei-Pill on colitis-associated colorectal cancer: an integrated transcriptomics, metabolomics, and experimental validation study. Phytomedicine. 2024;128:155509.","journal-title":"Phytomedicine"},{"issue":"6","key":"3397_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, et al. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23(6):445\u201360.","journal-title":"Nat Rev Drug Discov"},{"key":"3397_CR38","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S521346","author":"R Lisandrelli","year":"2025","unstructured":"Lisandrelli R, et al. Studying immunogenic cell death in human colorectal cancer organoids. Onco Targets Ther. 2025. https:\/\/doi.org\/10.2147\/OTT.S521346.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"3397_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54\u201361.","journal-title":"Nat Med"},{"issue":"29","key":"3397_CR40","doi-asserted-by":"crossref","first-page":"41571","DOI":"10.1021\/acsami.5c05498","volume":"17","author":"Y Tang","year":"2025","unstructured":"Tang Y, et al. Cantharidin-loaded nanomedicine modified with amphiphilic peptides induce immunogenic cell death to enhance PD-1 blockade. ACS Appl Mater Interfaces. 2025;17(29):41571\u201385.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"3397_CR41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.62347\/XNVR3799","volume":"15","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, et al. Triptolide induces immunogenic cell death in cervical cancer cells via ER stress and redox modulation. Am J Cancer Res. 2025;15(1):69\u201383.","journal-title":"Am J Cancer Res"},{"issue":"8","key":"3397_CR42","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41418-017-0044-9","volume":"25","author":"L Bezu","year":"2018","unstructured":"Bezu L, et al. eIF2\u03b1 phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ. 2018;25(8):1375\u201393.","journal-title":"Cell Death Differ"},{"issue":"2","key":"3397_CR43","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.celrep.2015.12.029","volume":"14","author":"T Xia","year":"2016","unstructured":"Xia T, et al. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 2016;14(2):282\u201397.","journal-title":"Cell Rep"},{"key":"3397_CR44","volume":"157","author":"H Zheng","year":"2023","unstructured":"Zheng H, et al. Epigenetically suppressed tumor cell intrinsic STING promotes tumor immune escape. Biomed Pharmacother. 2023;157:114033.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3397_CR45","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41420-025-02862-6","volume":"11","author":"H Chai","year":"2025","unstructured":"Chai H, et al. Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment. Cell Death Discov. 2025;11(1):559.","journal-title":"Cell Death Discov"},{"issue":"9","key":"3397_CR46","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.4049\/jimmunol.1102737","volume":"189","author":"YP Liu","year":"2012","unstructured":"Liu YP, et al. Endoplasmic reticulum stress regulates the innate immunity critical transcription factor IRF3. J Immunol. 2012;189(9):4630\u20139.","journal-title":"J Immunol"},{"key":"3397_CR47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.ircmb.2019.10.004","volume":"350","author":"J Sprooten","year":"2020","unstructured":"Sprooten J, Garg AD. Type I interferons and endoplasmic reticulum stress in health and disease. Int Rev Cell Mol Biol. 2020;350:63\u2013118.","journal-title":"Int Rev Cell Mol Biol"},{"key":"3397_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-026-02345-8","author":"S Luo","year":"2026","unstructured":"Luo S, Zheng S. PSD3 links autophagic flux to MHC-I-associated immune modulation in esophageal squamous cell carcinoma. Apoptosis. 2026. https:\/\/doi.org\/10.1007\/s10495-026-02345-8.","journal-title":"Apoptosis"},{"key":"3397_CR49","volume":"15","author":"C Guo","year":"2025","unstructured":"Guo C, Wang C. Microbiota-host metabolism reprogramming in colorectal cancer: from pathogenesis to precision therapies. Front Oncol. 2025;15:1713614.","journal-title":"Front Oncol"},{"key":"3397_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157400","author":"F Li","year":"2025","unstructured":"Li F, et al. Mitochondrial metabolism in T-cell exhaustion. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26157400.","journal-title":"Int J Mol Sci"},{"key":"3397_CR51","volume":"16","author":"Z Ma","year":"2025","unstructured":"Ma Z, et al. Metabolic syndrome in colorectal cancer liver metastasis: metabolic reprogramming and microenvironment crosstalk. Front Immunol. 2025;16:1653442.","journal-title":"Front Immunol"},{"issue":"3","key":"3397_CR52","first-page":"170","volume":"5","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Ginsenoside Rg1 improves anti-tumor efficacy of adoptive cell therapy by enhancing T cell effector functions. Blood Sci. 2023;5(3):170\u20139.","journal-title":"Blood Sci"},{"issue":"5","key":"3397_CR53","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ccell.2021.03.004","volume":"39","author":"A Bertocchi","year":"2021","unstructured":"Bertocchi A, et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell. 2021;39(5):708\u2013e72411.","journal-title":"Cancer Cell"},{"issue":"21","key":"3397_CR54","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1158\/0008-5472.CAN-24-4425","volume":"85","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, et al. Gut microbiota-mediated bile acid metabolism regulates colorectal cancer liver metastasis by altering neutrophil recruitment. Cancer Res. 2025;85(21):4081\u201398.","journal-title":"Cancer Res"},{"issue":"4","key":"3397_CR55","doi-asserted-by":"crossref","first-page":"575","DOI":"10.5009\/gnl210177","volume":"16","author":"N Yuan","year":"2022","unstructured":"Yuan N, et al. Gut Microbiota Alteration Influences Colorectal Cancer Metastasis to the Liver by Remodeling the Liver Immune Microenvironment. Gut Liver. 2022;16(4):575\u201388.","journal-title":"Gut Liver"},{"key":"3397_CR56","volume":"149","author":"M Zheng","year":"2025","unstructured":"Zheng M, et al. Shenling Baizhu powder potentiates immunotherapy response: putative roles of gut microbial remodeling and fatty acid metabolism modulation. Phytomedicine. 2025;149:157559.","journal-title":"Phytomedicine"},{"key":"3397_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2026.124326","author":"ZZ Ye","year":"2026","unstructured":"Ye ZZ, Luo X. Decoding the mitochondrial metabolic engine for tumor metastasis and clinical therapeutic opportunities. Life Sci. 2026. https:\/\/doi.org\/10.1016\/j.lfs.2026.124326.","journal-title":"Life Sci"},{"issue":"2","key":"3397_CR58","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.gastro.2019.06.048","volume":"158","author":"M Song","year":"2020","unstructured":"Song M, Chan AT, Sun J. Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. Gastroenterology. 2020;158(2):322\u201340.","journal-title":"Gastroenterology"},{"key":"3397_CR59","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1038\/ncomms7342","volume":"6","author":"SJ O\u2019Keefe","year":"2015","unstructured":"O\u2019Keefe SJ, et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun. 2015;6:6342.","journal-title":"Nat Commun"},{"key":"3397_CR60","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5667","author":"C Jim\u00e9nez-Cortegana","year":"2024","unstructured":"Jim\u00e9nez-Cortegana C, et al. Impact of obesity\u2011associated myeloid\u2011derived suppressor cells on cancer risk and progression (Review). Int J Oncol. 2024. https:\/\/doi.org\/10.3892\/ijo.2024.5667.","journal-title":"Int J Oncol"},{"issue":"4","key":"3397_CR61","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/gutjnl-2016-313413","volume":"67","author":"Y Cao","year":"2018","unstructured":"Cao Y, et al. Long-term use of antibiotics and risk of colorectal adenoma. Gut. 2018;67(4):672\u20138.","journal-title":"Gut"},{"issue":"9","key":"3397_CR62","volume":"2","author":"F Wang","year":"2021","unstructured":"Wang F, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2(9):100383.","journal-title":"Cell Rep Med"},{"issue":"6","key":"3397_CR63","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00262-021-03083-3","volume":"71","author":"K Yang","year":"2022","unstructured":"Yang K, et al. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: a multicenter study. Cancer Immunol Immunother. 2022;71(6):1443\u201351.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"3397_CR64","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00262-025-04237-3","volume":"74","author":"W Zhang","year":"2025","unstructured":"Zhang W, et al. Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR\/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial. Cancer Immunol Immunother. 2025;74(12):381.","journal-title":"Cancer Immunol Immunother"},{"key":"3397_CR65","volume":"14","author":"Y-C Yao","year":"2026","unstructured":"Yao Y-C, et al. Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study). Gastroenterol Rep. 2026;14:goag009.","journal-title":"Gastroenterol Rep"},{"key":"3397_CR66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","volume":"181","author":"Y Guo","year":"2023","unstructured":"Guo Y, et al. Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. Eur J Cancer. 2023;181:26\u201337.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3397_CR67","volume":"18","author":"HY Qin","year":"2026","unstructured":"Qin HY, et al. Clinical efficacy of Fuzheng Jiedu Xiaoyong granules in advanced colorectal cancer (spleen deficiency and stasis toxin syndrome). World J Gastrointest Oncol. 2026;18(2):113922.","journal-title":"World J Gastrointest Oncol"},{"key":"3397_CR68","volume":"338","author":"M Wang","year":"2025","unstructured":"Wang M, et al. Traditional Chinese medicine enhances the effectiveness of immune checkpoint inhibitors in tumor treatment: a mechanism discussion. J Ethnopharmacol. 2025;338:118955.","journal-title":"J Ethnopharmacol"},{"key":"3397_CR69","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001692","author":"JJ Zhu","year":"2023","unstructured":"Zhu JJ, et al. Anti-tumour effect of Huangqin decoction on colorectal cancer mice through microbial butyrate mediated PI3K\/Akt pathway suppression. J Med Microbiol. 2023. https:\/\/doi.org\/10.1099\/jmm.0.001692.","journal-title":"J Med Microbiol"},{"issue":"2","key":"3397_CR70","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11655-023-3554-y","volume":"30","author":"L-M Gu","year":"2024","unstructured":"Gu L-M, et al. Huangqin decoction delays progress of colitis-associated carcinogenesis by regulating Nrf2\/HO-1 antioxidant signal pathway in mice. Chin J Integr Med. 2024;30(2):135\u201342.","journal-title":"Chin J Integr Med"},{"key":"3397_CR71","volume":"346","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Huang-qin decoction alleviates deoxycholic acid-induced colorectal cancer in mice by regulating gut microbiota. J Ethnopharmacol. 2025;346:119715.","journal-title":"J Ethnopharmacol"},{"key":"3397_CR72","doi-asserted-by":"crossref","unstructured":"Wang W, et al. Baicalein from Scutellaria baicalensis mitigates oxidative stress through the IIS pathway in a C. elegans model of ulcerative colitis. Front Pharmacol, 2025.16\u20132025.","DOI":"10.3389\/fphar.2025.1592244"},{"key":"3397_CR73","volume":"141","author":"J Zhang","year":"2025","unstructured":"Zhang J, et al. Scutellaria baicalensis extracts restrict intestinal epithelial cell ferroptosis by regulating lipid peroxidation and GPX4\/ACSL4 in colitis. Phytomedicine. 2025;141:156708.","journal-title":"Phytomedicine"},{"issue":"14","key":"3397_CR74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411504","volume":"24","author":"M Terrin","year":"2023","unstructured":"Terrin M, et al. Checkpoint inhibitor-induced colitis: from pathogenesis to management. Int J Mol Sci. 2023;24(14):11504.","journal-title":"Int J Mol Sci"},{"key":"3397_CR75","doi-asserted-by":"crossref","unstructured":"Zheng J, et al. ICI-induced cardiovascular toxicity: mechanisms and immune reprogramming therapeutic strategies. Front Immunol, 2025. 16\u20132025.","DOI":"10.3389\/fimmu.2025.1550400"},{"issue":"1","key":"3397_CR76","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12672-025-04367-1","volume":"17","author":"Y Li","year":"2026","unstructured":"Li Y, et al. The gut microbiome in colorectal cancer: mechanisms of carcinogenesis and emerging microbiota-targeted therapies. Discover Oncol. 2026;17(1):181.","journal-title":"Discover Oncol"},{"issue":"1","key":"3397_CR77","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41522-025-00883-8","volume":"12","author":"J Bautista","year":"2026","unstructured":"Bautista J, et al. Gut microbiome\u2013driven colorectal cancer via immune, metabolic, neural, and endocrine axes reprogramming. npj Biofilms Microbiomes. 2026;12(1):21.","journal-title":"npj Biofilms Microbiomes"},{"issue":"1","key":"3397_CR78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13020-023-00719-7","volume":"18","author":"J-F Chen","year":"2023","unstructured":"Chen J-F, et al. Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. Chin Med. 2023;18(1):14.","journal-title":"Chin Med"},{"issue":"1","key":"3397_CR79","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13020-026-01438-5","volume":"21","author":"Q Bu","year":"2026","unstructured":"Bu Q, et al. Unveiling medication patterns in traditional Chinese medicine for the prevention of colorectal cancer recurrence: from potential combinations to validation of components and targets. Chin Med. 2026;21(1):160.","journal-title":"Chin Med"},{"key":"3397_CR80","doi-asserted-by":"crossref","unstructured":"Zhexian L, et al. Clinical application prospects of traditional Chinese medicine as adjuvant therapy for metabolic reprogramming in colorectal cancer. Front Immunol, 2025. 16\u20132025.","DOI":"10.3389\/fimmu.2025.1630279"},{"issue":"7","key":"3397_CR81","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.chom.2026.05.030","volume":"34","author":"S Pekel","year":"2026","unstructured":"Pekel S, et al. Meta-analysis reveals microbiome signatures for colorectal cancer that are universal across age groups and sequencing methods. Cell Host Microbe. 2026;34(7):1462\u2013e14765.","journal-title":"Cell Host Microbe"},{"key":"3397_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101290","author":"S Ogino","year":"2026","unstructured":"Ogino S, et al. Unique role of the prospective cohort incident-tumor biobank method in etiological research. Lancet Reg Health Am. 2026. https:\/\/doi.org\/10.1016\/j.lana.2025.101290.","journal-title":"Lancet Reg Health Am"},{"issue":"12","key":"3397_CR83","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10654-025-01322-w","volume":"40","author":"S Ogino","year":"2025","unstructured":"Ogino S, et al. The early-onset cancer epidemics: evidence synthesis using the prospective cohort incident-tumor biobank method. Eur J Epidemiol. 2025;40(12):1405\u201317.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"3397_CR84","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2452237","volume":"17","author":"S Ugai","year":"2025","unstructured":"Ugai S, et al. Long-term yogurt intake and colorectal cancer incidence subclassified by Bifidobacterium abundance in tumor. Gut Microbes. 2025;17(1):2452237.","journal-title":"Gut Microbes"},{"issue":"10","key":"3397_CR85","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41416-026-03373-6","volume":"134","author":"K Matsuda","year":"2026","unstructured":"Matsuda K, et al. Tumor vessel phenotype in colorectal cancer microenvironment according to age at diagnosis. Br J Cancer. 2026;134(10):1375\u201386.","journal-title":"Br J Cancer"},{"issue":"21","key":"3397_CR86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110494","volume":"26","author":"A Gandhi","year":"2025","unstructured":"Gandhi A, Master S, Bhise V. When nature meets oncology: unraveling herb\u2013drug interactions in cancer therapy. Int J Mol Sci. 2025;26(21):10494.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"3397_CR87","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/94.16.1247","volume":"94","author":"RH Mathijssen","year":"2002","unstructured":"Mathijssen RH, et al. Effects of St. John\u2019s wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94(16):1247\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3397_CR88","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1080\/13880209.2021.1942927","volume":"59","author":"M Meng","year":"2021","unstructured":"Meng M, et al. Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. Pharm Biol. 2021;59(1):878\u201381.","journal-title":"Pharm Biol"},{"issue":"5","key":"3397_CR89","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/jphp.13067","volume":"71","author":"X Tian","year":"2019","unstructured":"Tian X, et al. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats. J Pharm Pharmacol. 2019;71(5):788\u201396.","journal-title":"J Pharm Pharmacol"},{"key":"3397_CR90","first-page":"179643","volume":"2013","author":"X Tian","year":"2013","unstructured":"Tian X, et al. Inhibitory effects of baicalin on the expression and activity of CYP3A induce the pharmacokinetic changes of midazolam in rats. Evid Based Complement Alternat Med. 2013;2013:179643.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3397_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ph18020280","author":"Y Xie","year":"2025","unstructured":"Xie Y, et al. Clinical progress of fruquintinib in colorectal cancer: an overview. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18020280.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3397_CR92","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00882","author":"M-V Zeng","year":"2023","unstructured":"Zeng M-V. The integration of nanomedicine with traditional Chinese medicine: drug delivery of natural products and other opportunities. Mol Pharm. 2023. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00882.","journal-title":"Mol Pharm"},{"issue":"9","key":"3397_CR93","volume":"53","author":"J Zou","year":"2025","unstructured":"Zou J, et al. Pharmacological mechanisms and pharmacokinetic analysis of anti-tumor components in Chinese herbal medicine. Chin J Anal Chem. 2025;53(9):100590.","journal-title":"Chin J Anal Chem"},{"issue":"1","key":"3397_CR94","volume":"25","author":"P Zhang","year":"2024","unstructured":"Zhang P, et al. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. Brief Bioinform. 2024;25(1):bbad518.","journal-title":"Brief Bioinform"},{"issue":"7","key":"3397_CR95","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/ph18071074","volume":"18","author":"L Yang","year":"2025","unstructured":"Yang L, et al. Network Pharmacology-Driven Sustainability: AI and Multi-Omics Synergy for Drug Discovery in Traditional Chinese Medicine. Pharmaceuticals. 2025;18(7):1074.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"3397_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59822-y","volume":"16","author":"T Liu","year":"2025","unstructured":"Liu T, et al. Building a unified model for drug synergy analysis powered by large language models. Nat Commun. 2025;16(1):4537.","journal-title":"Nat Commun"},{"issue":"1","key":"3397_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52814-w","volume":"14","author":"T Abd El-Hafeez","year":"2024","unstructured":"Abd El-Hafeez T, et al. Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs. Sci Rep. 2024;14(1):2428.","journal-title":"Sci Rep"},{"key":"3397_CR98","doi-asserted-by":"crossref","unstructured":"Trac QT, et al. Pathway activation model for personalized prediction of drug synergy. eLife Sciences Publications, Ltd.; 2025.","DOI":"10.7554\/eLife.100071.4"},{"issue":"1","key":"3397_CR99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/cimb48010015","volume":"48","author":"J Montoya Montoya","year":"2026","unstructured":"Montoya Montoya J, et al. Effect of Gut Microbiota Alteration on Colorectal Cancer Progression in an In Vivo Model: Histopathological and Immunological Evaluation. Curr Issues Mol Biol. 2026;48(1):15.","journal-title":"Curr Issues Mol Biol"},{"issue":"10","key":"3397_CR100","first-page":"e00436","volume":"12","author":"S Yang","year":"2024","unstructured":"Yang S, et al. A novel clinically relevant human fecal microbial transplantation model in humanized mice. Microbiol Spectr. 2024;12(10):e00436\u201324.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"3397_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-025-00710-x","volume":"26","author":"X Wang","year":"2025","unstructured":"Wang X, et al. Fecal microbiota transplantation enhanced the effect of chemoimmunotherapy by restoring intestinal microbiota in LLC tumor-bearing mice. BMC Immunol. 2025;26(1):30.","journal-title":"BMC Immunol"},{"issue":"12","key":"3397_CR102","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41419-024-07266-5","volume":"15","author":"A Esposito","year":"2024","unstructured":"Esposito A, et al. Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance. Cell Death Dis. 2024;15(12):878.","journal-title":"Cell Death Dis"},{"issue":"2","key":"3397_CR103","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.111827","volume":"28","author":"SA Revilla","year":"2025","unstructured":"Revilla SA, et al. Tumor-derived colorectal cancer organoids induce a unique Treg cell population by directing CD4+ T cell differentiation. iScience. 2025;28(2):111827.","journal-title":"iScience"},{"issue":"6","key":"3397_CR104","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ccell.2025.03.011","volume":"43","author":"Z Tang","year":"2025","unstructured":"Tang Z, et al. Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures. Cancer Cell. 2025;43(6):1025-1044.e14.","journal-title":"Cancer Cell"},{"issue":"1","key":"3397_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65421-8","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, et al. Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer. Nat Commun. 2025;16(1):10435.","journal-title":"Nat Commun"},{"issue":"3","key":"3397_CR106","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.152911","volume":"230","author":"M Le Rochais","year":"2025","unstructured":"Le Rochais M, et al. A tertiary lymphoid structures-based pathological score predicts survival and recurrence in colorectal cancer patients. Immunobiology. 2025;230(3):152911.","journal-title":"Immunobiology"},{"key":"3397_CR107","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-1-0716-4184-2_9","volume":"2864","author":"M Le Rochais","year":"2025","unstructured":"Le Rochais M, et al. Imaging Mass Cytometry to Decipher the Maturation of Tertiary Lymphoid Structures. Methods Mol Biol. 2025;2864:159\u201379.","journal-title":"Methods Mol Biol"},{"key":"3397_CR108","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1147480","volume":"14","author":"M Le Rochais","year":"2023","unstructured":"Le Rochais M, et al. Deciphering the maturation of tertiary lymphoid structures in cancer and inflammatory diseases of the digestive tract using imaging mass cytometry. Front Immunol. 2023;14:1147480.","journal-title":"Front Immunol"},{"issue":"1","key":"3397_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-94664-0","volume":"15","author":"M Le Rochais","year":"2025","unstructured":"Le Rochais M, et al. Automated classification of tertiary lymphoid structures in colorectal cancer using TLS-PAT artificial intelligence tool. Sci Rep. 2025;15(1):9845.","journal-title":"Sci Rep"},{"issue":"11","key":"3397_CR110","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21057","volume":"9","author":"G Ming-Bin","year":"2023","unstructured":"Ming-Bin G, et al. TCM syndrome differentiation in colorectal cancer patients assisted by differences in gut microbiota: an exploratory study. Heliyon. 2023;9(11):e21057.","journal-title":"Heliyon"},{"key":"3397_CR111","doi-asserted-by":"crossref","unstructured":"Zou M, et al. Serum metabolomics analysis of biomarkers and metabolic pathways in patients with colorectal cancer associated with spleen-deficiency and qi-stagnation syndrome or damp-heat syndrome: a prospective cohort study. Front Oncol, 2023. 13\u20132023.","DOI":"10.3389\/fonc.2023.1190706"},{"issue":"1","key":"3397_CR112","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","volume":"9","author":"X-P Duan","year":"2024","unstructured":"Duan X-P, et al. New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct Target Therapy. 2024;9(1):57.","journal-title":"Signal Transduct Target Therapy"},{"issue":"16_suppl","key":"3397_CR113","doi-asserted-by":"crossref","first-page":"e23005","DOI":"10.1200\/JCO.2024.42.16_suppl.e23005","volume":"42","author":"HY Lee","year":"2024","unstructured":"Lee HY, et al. Precision oncology clinical trials: a systematic review of phase II clinical trials with biomarker-driven, adaptive design. J Clin Oncol. 2024;42(16_suppl):e23005.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3397_CR114","first-page":"253","volume":"2","author":"MP Farrell","year":"2003","unstructured":"Farrell MP, Kummar S. Phase I\/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2003;2(4):253\u20136.","journal-title":"Clin Colorectal Cancer"},{"key":"3397_CR115","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, & Center for Drug Evaluation and Research. (2016). Botanical drug development: Guidance for industry. U.S. Food and Drug Administration. fda.gov"},{"issue":"3","key":"3397_CR116","first-page":"358","volume":"12","author":"Y Yan","year":"2025","unstructured":"Yan Y, et al. Development and validation of the patient-reported traditional Chinese medicine kidney deficiency pattern scale for patients with colorectal cancer. J Tradit Chin Med Sci. 2025;12(3):358\u201363.","journal-title":"J Tradit Chin Med Sci"},{"key":"3397_CR117","doi-asserted-by":"crossref","unstructured":"Mitchell, C. A., Roe, A. L., Auerbach, S., Bascoul, C., Embry, M., Ferguson, S., ... & Rider, C. (2025). From vision to reality: five years of the Botanical Safety Consortium. Pharmaceutical Biology, 63(1), 800-818.","DOI":"10.1080\/13880209.2025.2583832"},{"issue":"7","key":"3397_CR118","volume":"17","author":"T-H Guo","year":"2025","unstructured":"Guo T-H, et al. Associations between blood metabolite levels and gastrointestinal cancer risk: a preliminary untargeted metabolomics study. World J Gastrointest Oncol. 2025;17(7):104860.","journal-title":"World J Gastrointest Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03397-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03397-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03397-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:13Z","timestamp":1792096933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03397-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":118,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3397"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03397-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests that may have influenced in this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that Gen AI and large language model (LLM) were used in the creation of this manuscript. Generative AI items like instatext, wordvice, and Deep L were used for structural editing and improve handwriting of the text.","order":2,"name":"Ethics","label":"Generative AI","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper is submitted with the agreement of all its co-authors and the author list has been approved by all authors.","order":3,"name":"Ethics","label":"Author Agreement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics, consent to participate, and consent to publish declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial no","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"281"}}